Ergoteles’s LeMaitre Vascular LMAT Stock Holding History

Ergoteles’s Portfolio LMAT Stock Details LMAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,650	Closed	-$342K	–	1289
2023 Q1	$342K	Buy	+6,650	New	+$323K	0.01%	859

Other funds holding LMAT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Ergoteles's LMAT Position: Q2 2023 in Review

Ergoteles sold out of LeMaitre Vascular (LMAT) in Q2 2023, closing a stake of 6,650 shares — an estimated $342K sold.

Ergoteles first reported a position in LMAT in Q1 2023 and held it in 1 quarter. The position peaked at $342K in Q1 2023. 212 funds tracked by Wall St. Rank hold LMAT as of Q2 2023.

Ergoteles reported no remaining LeMaitre Vascular position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 6,650 LeMaitre Vascular shares in Q2 2023, an estimated $342K.
Ergoteles first reported a position in LeMaitre Vascular in Q1 2023 and held it in 1 quarter.
Ergoteles's LeMaitre Vascular position peaked at $342K in Q1 2023.
212 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.